Eli Lilly and Company (NYSE:LLY) major shareholder Lilly Endowment Inc sold 180,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 25th. The stock was sold at an average price of $80.85, for a total transaction of $14,553,000.00. Following the transaction, the insider now directly owns 122,896,904 shares of the company’s stock, valued at $9,936,214,688.40. The sale was disclosed in a document filed with the SEC, which is available through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Shares of LLY opened at $82.73 on Friday. The firm has a market capitalization of $88,896.81, a price-to-earnings ratio of 19.33, a P/E/G ratio of 1.40 and a beta of 0.26. Eli Lilly and Company has a fifty-two week low of $73.69 and a fifty-two week high of $89.09. The company has a current ratio of 1.32, a quick ratio of 1.01 and a debt-to-equity ratio of 0.85.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, April 24th. The company reported $1.34 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.13 by $0.21. The company had revenue of $5.70 billion for the quarter, compared to analyst estimates of $5.51 billion. Eli Lilly and had a net margin of 4.82% and a return on equity of 36.01%. Eli Lilly and’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same quarter last year, the business earned $0.98 EPS. sell-side analysts forecast that Eli Lilly and Company will post 5.16 earnings per share for the current fiscal year.

Several research firms have commented on LLY. BMO Capital Markets reaffirmed a “hold” rating and issued a $79.00 target price on shares of Eli Lilly and in a research note on Tuesday. Jefferies Group set a $90.00 target price on shares of Eli Lilly and and gave the stock a “buy” rating in a research note on Friday, April 13th. HC Wainwright reaffirmed a “buy” rating on shares of Eli Lilly and in a research note on Wednesday, April 18th. Credit Suisse Group set a $80.00 target price on shares of Eli Lilly and and gave the stock a “hold” rating in a research note on Sunday, April 22nd. Finally, Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $87.00 target price for the company in a research note on Wednesday, April 11th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $93.11.

Institutional investors and hedge funds have recently made changes to their positions in the business. Gradient Investments LLC acquired a new position in shares of Eli Lilly and in the 4th quarter valued at $103,000. Avestar Capital LLC acquired a new position in shares of Eli Lilly and during the 4th quarter valued at $100,000. Front Row Advisors LLC acquired a new position in shares of Eli Lilly and during the 4th quarter valued at $137,000. Wealthcare Advisory Partners LLC acquired a new position in shares of Eli Lilly and during the 3rd quarter valued at $142,000. Finally, Fieldpoint Private Securities LLC acquired a new position in shares of Eli Lilly and during the 3rd quarter valued at $147,000. Institutional investors own 77.69% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Insider Buying and Selling by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.